Harvard Bioscience Q2 revenue meet estimates
Overview
Harvard Bioscience Q2 2025 revenue in line with analyst expectations, per LSEG data
Adjusted EPS for Q2 meets analyst estimates, indicating stable performance
Company signs credit amendment, extending refinance deadline to Dec 5, 2025
Outlook
Harvard Bioscience expects Q3 2025 revenue between $19 mln and $21 mln
Company anticipates Q3 2025 gross margin of 56% to 58%
Harvard Bioscience sees improved operations and strong financial discipline
Company aims for revenue growth and margin expansion in 2026
Result Drivers
CASH FLOW IMPROVEMENT - Cash provided by operations improved to $2.8 mln from a negative $0.8 mln in Q2 2024
CREDIT AMENDMENT - New credit amendment signed, extending refinance deadline to December 5, 2025
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Meet | $20.45 mln | $20.40 mln (2 Analysts) |
Q2 Adjusted EPS | Meet | -$0.01 | -$0.01 (2 Analysts) |
Q2 EPS |
| -$0.05 |
|
Q2 Net Income |
| -$2.28 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Harvard Bioscience Inc is $3.00, about 82.4% above its August 8 closing price of $0.53
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 6 three months ago
Press Release: ID:nGNX1ZYVBM
Related Articles
Seth Klarman Portfolio
TradingKey - Seth Klarman, the Baupost value investor, long had the distinction of navigating doubt with surgeon-like precision. The technique is married to asymmetric bets, deep margin-of-safety work, and, of course, in many cases, a dash of contrarian genius..jfif)
U.S. Stock Strategy: The Rapid Development of AI Signals a Promising Future
TradingKey - Since Trump announced a 90-day suspension of the "reciprocal tariffs" imposed on certain countries on 9 April this year, all three major U.S. stock indices have recorded significant gains. Looking ahead, against the backdrop of easing global trade frictions.
China July Inflation Commentary: CPI Exceeds Expectations
TradingKey - On 9 August 2025, China's National Bureau of Statistics released inflation data for July. The Consumer Price Index (CPI) rose by 0.4% month-on-month, reversing the previous month's 0.1% decline, while remaining unchanged year-on-year. Core CPI increased by 0.8% year-on-year.
U.S. CPI Preview: Bullish Outlook for U.S. Stocks Continues
TradingKey - On 12 August 2025, the U.S. will release its July CPI data. Market consensus forecasts a year-over-year headline CPI increase of 2.8% and a core CPI rise of 3%, both up 0.1 percentage points from June. We align with these widely held market expectations. Breaking it down by category...
[IN-DEPTH ANALYSIS] LULU: Can it Recover from the Drop?
TradingKey - Thesis Among the stocks of the twenty largest clothing companies by revenue, Lululemon has the fifth lowest forward PE ratio. With all the negative sentiment revolving around the stock, we believe their multiple should be higher.
